Grantee Spotlight: SAKK 01/18 Trial Drives Change in Global Cancer Guidelines
August 7, 2025
We’re proud to share a major milestone achieved by one of our completed grants: the “SAKK 01/18 trial: Reduced intensity radio-chemotherapy for stage IIA/B seminoma” has led to a significant update in the National Comprehensive Cancer Network (NCCN) guidelines (image 1).
Led by Dr. Alexandros Papachristofilou of the University Hospital Basel—who also serves on the Rising Tide Foundation for Clinical Cancer Research’s Advisory Board—this study demonstrated that a significantly reduced intensity of radiotherapy is both safe and effective for men with stage IIA/B seminoma. The result: fewer long-term side effects and a more patient-centered approach to cancer care.
This achievement reflects the power of evidence-based research to shape global standards and improve lives. Congratulations to Dr. Papachristofilou and the entire team behind this success!
Image 1. Extract from Testicular Cancer – Guidelines Detail. Highlighted in red – the change in the guidelines based on Dr. Papachristofilou’ trial.
In the video below, Dr. Papachristofilou and patient partner Kai Ronecker—who served as an advisor on the project—share the story behind the trial from both the clinician’s and the patient’s perspectives. Diagnosed with seminoma at the age of 25, Mr. Ronecker reflects on the transformative impact of his cancer journey. His active advocacy led to an amendment of the trial protocol, expanding the inclusion criteria to also allow patients with recurrent cancer. He highlights how being meaningfully involved in the trial gave him a renewed sense of agency over his life.